SCHEMBL120177

SCHEMBL120177

Cc1cc(Br)ccc1S(=O)(=O)NCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.66
CYP1A2 P05177 2/20 0.59
CYP2C19 P33261 1/20 0.59
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
KMT2A Q03164 1/20 0.58
MAPT P10636 3/20 0.57
TP53 P04637 3/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
POLB P06746 1/20 0.56
CA12 O43570 2/20 0.53
CA9 Q16790 2/20 0.53
NPC1 O15118 1/20 0.52
NR2F2 P24468 1/20 0.52
NOD2 Q9HC29 1/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPK1 P28482 1/20 0.52
CYP3A4 P08684 1/20 0.51
ATM Q13315 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16568639 0.84 LMNA (0.68) LMNACYP1A2CYP2C19KMT2AMAPT
SCHEMBL4521279 0.83 TDP1 (0.64) LMNACA1CA2KMT2ATP53
SCHEMBL119469 0.82 KMT2A (0.66) LMNACYP1A2CYP2C19KMT2AMAPT
SCHEMBL119909 0.82 LMNA (0.77) LMNACYP1A2CYP2C19KMT2AMAPT
SCHEMBL407668 0.81 CA12 (0.61) LMNACYP1A2CYP2C19CA2POLB
SCHEMBL16098346 0.80 CA1 (0.66) LMNACA1CA2SMN1; SMN2NPC1
SCHEMBL31113886 0.79 KMT2A (0.62) LMNACYP1A2CYP2C19KMT2AMAPT
SCHEMBL4520487 0.79 CA1 (0.58) LMNACA1CA2KMT2AMAPT
SCHEMBL31113449 0.79 ALDH1A1 (0.74) LMNACYP1A2CYP2C19MAPTSMN1; SMN2
SCHEMBL5269149 0.77 CA1 (0.59) LMNACA1CA2MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102427810-A Sulfamoylbenzoic acid derivatives as TRPM8 antagonists RAQUALIA PHARMA INC 2012-04-25 CN disclosed
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2012-04-19 US disclosed
EP-2424517-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RaQualia Pharma Inc (JP) 2012-03-07 EP disclosed
WO-2010125831-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094964-A1 SULFAMOYL BENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM5, TRPM6 LMNA 3339/4885CYP1A2 2926/4885CYP2C19 1574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.